Evidence map›Paper›PMID 39941756›Full record

ReviewCancers2025

Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review.

Catarina S Padilla, Cristiane D Bergerot, Kim Dijke, Evelyne Roets, Gabriela Boková, Veronika Innerhofer, Samantha C Sodergren, Rosanna Mancari, Cristiana Bergamini, Kirsty M Way and 7 more

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Catarina S PadillaDepartment of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-1821-3760
Cristiane D BergerotPsycho-Oncology Services, Oncoclinicas & Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo 04543-906, Brazil.ORCID 0000-0003-0037-0303
Kim DijkeDepartment of Gastrointestinal Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.
Evelyne RoetsDepartment of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0001-9733-7619
Gabriela BokováInternational Accreditation Office, Masaryk Memorial Cancer Institute, 7656 53 Brno, Czech Republic.ORCID 0009-0003-7050-1409
Veronika InnerhoferDepartment of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Samantha C SodergrenSchool of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0001-8755-146X
Rosanna MancariGynaecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-9726-3653
Cristiana BergaminiFondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.ORCID 0000-0001-7616-5125
Kirsty M WaySchool of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Olga SapoznikovInternational Accreditation Office, Masaryk Memorial Cancer Institute, 7656 53 Brno, Czech Republic.ORCID 0000-0002-3733-5352
Jacobus A BurgersDepartment of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-0218-8436
Daniel DejacoDepartment of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0001-9176-7415
Margot E T TesselaarDepartment of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.
Winette T A van der GraafDepartment of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0001-7549-3338
Olga HussonDepartment of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-1387-8686
EORTC Quality of Life Group

Funding

THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE GROUP 003-2022
6 · The paper itself

Abstract

backgroundHealth-related quality of life (HRQoL) is an important patient-reported outcome for all cancer patients, including adult patients with rare solid cancers. However, current knowledge of HRQoL in this population is limited, which hinders the delivery of personalized care. This review aimed to explore the heterogeneity of HRQoL among adult patients with a solid rare cancer across the ten European Reference Network for Rare Adult Solid Cancers (EURACAN) domains and to summarize the HRQoL measures used in clinical research.

methodsA systematic literature search was conducted to identify all clinical studies assessing HRQoL in adult patients with a solid rare cancer. Four databases (MEDLINE, PubMed, PsycINFO, and Web of Science/Scopus) were searched (February 2023).

resultsThe search yielded 18,704 articles, of which 1416 articles were fully screened and 463 were eligible for analysis. Of these, 397 studies used generic tools to assess HRQoL, while 270 used tumor-specific instruments. Three EURACAN domains (sarcoma, endocrine tumors, and thoracic tumors) primarily assessed HRQoL using generic questionnaires. Additionally, the rare gynecological tumor, rare male genitourinary, and sarcoma EURACAN domains lacked specific HRQoL measures. Brain, head and neck, and uveal melanoma EURACAN domains used tumor- or domain-specific questionnaires in more than half of the studies.

conclusionsThis state-of-the-art literature review shows that HRQoL assessment is gradually becoming more prevalent in adult solid rare cancer research. A combination of generic, tumor-specific, and domain-specific questionnaires across various rare cancer domains has proven effective in capturing a broad range of HRQoL issues. However, many EURACAN domains still lack specific strategies for assessing HRQoL, which limits the ability to fully understand and address patients' experiences. Future research should prioritize developing comprehensive and robust HRQoL measurement strategies and tools to enable meaningful clinical research and to ensure that the patient voice is incorporated in their clinical care.

Indexed as

adult rare solid cancersEURACANhealth-related quality of lifesystematic review

Identifiers

PMID39941756
PMCPMC11816368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.